It is important to remember that as for any medical treatment, improvements cannot be guaranteed. Please contact us for more information regarding the possible improvements for a particular case.
Stem Cell Quality and Quantity Ensured
Different types of stem cells for different needs
Beike provides stem cells from two separate sources: umbilical cord blood and umbilical cord tissue. Umbilical cord related samples are donated by healthy mothers after normal births and are sent to Beike Biotech's laboratories for processing.
After reviewing the patient’s full medical information, our doctors will recommend which source of stem cells should be used for treatment. Our treatment protocols may include one or multiple types of stem cell in combination depending on each patient's specific condition.
Highest International Stem Cell Processing Standards
Beike Biotechnology is processing its own adult stem cells in its internationally accredited laboratories. The company has full control over the processing and quality control of all stem cell products, ensuring perfect safety and highest quality. Processing methods and facility are accredited by the American Association of Blood Banks (AABB), the highest international standard in the industry.
Below are video interviews recorded during treatment with Beike stem cells. The families showcased in these videos talk about their personal stories and their experience of the treatment including the improvement noticed. The improvements mentioned in these videos are typical, however it does not guarantee that all patients may have the same improvements.
Extensiveness: A complete supportive therapy program is provided daily to stimulate patient's freshly transplanted stem cells. The best improvement can only be obtain by supporting your stem cells.
Support: A full follow-up program is provided after the treatment and you will be asked to take part in it at 1, 3, 6 and 12 months after treatment. Access to our team after the treatment is very important as you may receive further advice to maximize improvements.
Learn More About Us
Founded in July 2005, Shenzhen Beike Biotechnology Co. Ltd. (hereinafter referred to as Beike Biotechnology) is a national high-tech enterprise specialized in clinical transformation and technical service of biological treatment technology of strategic emerging industries.
Get more information now
More About ONA
What is optic nerve atrophy (ONA)?
Optic nerve atrophy (ONA) is an umbrella term used to describe a number of conditions, which result in vision loss. Optic nerve atrophy can be classified according to the cause of the atrophy, accordingly:
What causes ONA?
The cause of ONA is dependent upon the type of atrophy present:
- Demyelinating ONA, also known as optic neuritis, occurs in conditions such as multiple sclerosis and other demyelinating and inflammatory conditions. Patients often present with rapid loss of vision in one eye, which may be loss in part or all of the visual field.
- Ischemic ONA results from occlusion of blood vessels supplying the optic nerve and can occur in conditions such as vasculitis, giant cell arteritis, granulomatosis with polyangiitis, and rheumatoid arthritis. Patients with ischemic ONA develop rapidly progressing loss of vision, often in the superior aspect of their visual field.
- Traumatic ONA results from direct injury to the optic nerve, often from blunt force or accidents such as motor vehicle collisions.
- Inflammatory ONA, also known as infiltrative neuropathy, results in destruction of the optic nerve from locally invading tumors, infection and autoimmune processes such as sarcoidosis.
How is ONA diagnosed?
ONA is diagnosed by extensive ophthalmological investigation which may include1:
- Visual field testing: visual field defects in optic neuropathies can take several patterns including central, diffuse, arcuate, and altitudinal defect. The pattern of visual filed defect is not specific of any etiology and almost any type of field defect can occur with any optic neuropathy. However, altitudinal defects are more common in ischemic optic neuropathies and central, or cecocentral defects frequently accompany toxic/nutritional and hereditary optic neuropathies.
- Electrophysiological testing: Visual evoked potential (VEP) are often abnormal in optic neuropathies. Although VEP is not necessary in the diagnosis of optic neuropathy, it can be useful in patients with early or sub-clinical optic neuropathy who may have normal pupillary responses and no discernible optic disc changes on clinical examination
- Optical coherence tomography: a relatively new technique which uses low coherence light to penetrate tissue and a camera to analyze the reflected image. By performing circular scans around the optic nerve head, the peripapillary nerve fiber layer can be analyzed. This has been useful in the follow up of patients with optic neuritis, traumatic optic neuropathy, and Leber’s hereditary optic neuropathy
Symptoms of ONA often include tunnel vision (also known as scotoma), blurred vision, and loss of other visual fields. These defects are diagnosed on further investigation using the aforementioned techniques.
What are the current treatments for ONA?
Currently, there are no effective treatments for ONA. Following destruction of the optic nerve, regeneration of neurons using conventional medical treatment is not possible. Therefore, treatment with novel therapies, such as stem cells, offers a promising hope that regeneration of vision in ONA patients may be a possibility.
How can stem cells restore optic nerve function in patients with ONA?
The mechanisms by which stem cells deliver their regenerative action are :
- Secretion of neurotrophic factors before or after differentiation. MSCs release certain neurotrophic growth factors including brain derived neurotrophic factor (BDNF) which may offer neuroprotection.
- Injection of MSC may result in anti-inflammatory effects, thereby increasing regeneration of neurons located within the optic nerve.
- Studies in mice have shown that injection of MSCs provided by intravitreal injection were shown to migrate to the surface of the retina and integrate into the nerve fiber layer ultimately forming the optic nerve.